Full version CV in pdf here

CURRICULUM VITAE: ROSSIGNOL Patrick
Born 15 April 1969, French
Professional address: Centre d'Investigation Clinique Pierre Drouin -INSERM CHU de Nancy
Institut lorrain du coeur et des vaisseaux Louis Mathieu, 4, rue du Morvan. 54500 Vandoeuvre-LèsNancy. France
Tel +33 (0)3 83 15 73 20 Cell + 33621673189 Fax +33(0)3 83 15 73 24 E-mail [email protected]
Bio-Sketch
Born 1969, married, 3 children, Patrick Rossignol, MD, PhD, is a Nephrologist and Vascular medicine
specialist, Professor of Therapeutics at the University of Lorraine, France. Since 2007, he has a position
of deputy Director in Nancy University Hospital Inserm Clinical Investigation Center, which is headed by
Professor Faiez Zannad, researcher in Inserm UMR_S1116, and is consultant in the University Hospital
Heart Failure and Hypertension Unit (ESH excellence Centre) as well as in a hemodialysis clinics within
a Disease Management program. He is mainly involved in clinical research, especially concerning
circulating biomarkers, in the settings of heart failure, hypertension, hemodialysis and vascular diseases.
He is also involved in translational basic research studies on the mechanisms of transition of
hypertension and metabolic disorders to the cardiorenal syndrome. He has been participating in 4 EU FP
programs: FP-6 (Ingenious HyperCare: from hypertension to Heart Failure) and FP-7 (MEDIA: Metabolic
road to DIAstolic heart Failure), EU FP7 HOMAGE (Heart failure OMics in AGEing), FIBRO-TARGETS
the 2 latter coordinated by F. Zannad (CIC Nancy, France) (2013-2018) and is an EURECA-m
(cardiorenal working group of ERA-EDTA) member since its creation in 2009 and got elected as board
member for 6 years in 2013. He is the PI of the largest academic CV outcome RCT in hemodialysis, led
in close collaboration with F-CRIN (ALCHEMIST) and steering committee member of 4 international
randomized clinical trials, including one led by EURECA-m. Since 2014, he is coordinating a French
network of excellence endorsed by F-CRIN (French Clinical research Infrastructure Network, the French
affiliate of ECRIN/ERIC: Cardiovascular and Renal Clinical Trialists (INI-CRCT).
He is also scientific committee member of an epidemiological cohort of acute heart failure (>2500 pts
recruited, French PHRC EPICAL2, PR in charge of the biobanking and of biomarker studies), and is
organizing with Nancy CIC the 4th Visit of the Stanislas Cohort (4000 participants) (20-y) : >1000 pts
recruited so far. He has published 85 peer review publications and is co-inventor of 5 biomarker
international patents filed by Inserm Transfert in the cardiorenal syndrome setting, and co-funder of the
SME CardioRenal diagnosticS.
Major field of interest:
Chronic Kidney Diseases, Heart failure, Hypertension, Aortic aneurysms, Aldosterone,
Biomarkers, Clinical trials
Education (degrees, dates, universities)
· Master degree in Biology and Pathology of the epithelia, 1998, University of Paris VI « Pierre et Marie
Curie »
· Medical Doctorate, specialty nephrology, 2000, University of Paris V « Necker-Enfants Malades »
· Complementary fellowship in Vascular medicine: 2004, University of Paris V « Necker- Enfants
Malades »
· Ph. D. “Biology and pharmacology of hemostasis”: 2005, University of Paris VII “Denis Diderot”
- Research heading certification: 2009, Nancy University
-Hypertension specialist (board certification by the European Society of Hypertension): 2011
Professional/research experience
· 11/2000-31/10/2002: Ph. D. student, INSERM Unit 460, Dr Michel, Paris.
· 11/2002-31/10/2003: fellowship in vascular biology, Center for Molecular and Vascular Biology,
Katholieke Universiteit Leuven (Belgium): Pr Lijnen, Pr Collen
· 11/2003-04/2006: Chief-Assistant, then Assistant Professor (05/2006-04-2007): Vascular Medicine and
Hypertension department, Pr Fiessinger, Hôpital Européen Georges Pompidou (Assistance Publique-
Hôpitaux de Paris), Paris, and Faculté de Médecine René Descartes-Paris V; associate researcher,
INSERM 765 (formerly U 428), Pr Emmerich.
· 05/2007- : Assistant-Professor (Therapeutics), delegate physician of the Nancy University Hospital &
INSERM Clinical Investigation Centre (Coordinating physician: Pr Zannad); associate researcher,
INSERM 961, Dr Lacolley, and consultant in the Nancy European Society of Hypertension Hypertension
Excellence centre
. 2008- : consultant, Association Lorraine de Traitement de l’Insuffisance rénale (in hemodialysis)
· 2010- : Professor of therapeutics
.Clinical Trial experience
. 2011: steering committee member of the international multicenter Hepzero randomized controlled trial
(heparin-free hemodialysis with EVODIAL vs. usual care) sponsored by Gambro. clinicaltrials.gov
NCT01318486. First Author of the protocol design manuscript (2013), senior author of the results
manuscript (in revision)
. 2012: PI of the multicenter ALCHEMIST placebo controlled vs. spironolactone in hemodialysis
randomized controlled morbimortality outcome trial funded by the French Ministery of Health (enrolment
started Q2 2013) NCT01848639
. 2013: steering committee member and French PI of the international multicenter LUng comet STudy,
LUST randomized controlled CV morbimortality outcome trial sponsored by ERA-EDTA (enrolment
started Q2 2013)
. 2013: Data Safety Monitoring Committee member (chair) of the French pilot randomized open label trial
comparing an intensive heart failure management program vs. usual care in elderly patients HF80
NCT01437371
. 2014: Data Safety Monitoring Committee member of the French PHRC (AP-HP as sponsor) Lanreotide
In Polycystic kidney disease Study (randomized, placebo controlled, double blind)
. Pathophysiological clinical studies experience. PI of the AMETHYST (Aneurysm,
METalloproteinases and HYpertension STudy), RESAA ((Reflet Sanguin de l’Activité des Anévrysmes
de l’Aorte abdominale chez l’homme), BIOMIC (Biomarkers of therapeutic modelization in heart failure
NCT01655134), R2C2 (Role of the renin angiotensin aldosterone system in the mechanisms of transition
to heart failure in abdominal obesity NCT01716819), EPICAL 2 biological collection, AAA endoprothèse
studies. With Nancy CIC, responsible of the Stanislas Cohort (4000 participants) 4th visit (20-y)
organization > 1000 pts recruited so far. NCT 01391442
Network research activities within EU FP: EU FP6: Ingenious Hypercare (Integrating Genomics,
Clinical Research and Care in Hypertension) coordinated by A. Zanchetti (Milan) (2007-2011); EU FP7
FAD (Fighting Aneurysmal Disease), coordinated by JB Michel (France) (2008-2012) ; EU FP7 MEDIA
Diastolic heart failure in the metabolic syndrome, coordinated by W. Paulus (Nederland) (2009- ); EU
FP7 HOMAGE (Heart failure OMics and AGEing), coordinated by F. Zannad (CIC Nancy, France)(2013-)
; EU FP7 FIBRO-TARGETS, coordinated by F. Zannad (CIC Nancy, France) (2013-). Since 2013: COST
ADMIRE network coordinated by F. Jaisser (AlDosterone and MIneralocorticoid REceptor
pathophysiology, clinical and therapeutic implications): he is the French representative of clinicians in
the Managing Committee. Within two Leducq consortia
on atherothrombosis respectively
coordinated by J-B Michel (Paris) and P. Libby (Boston) ( “Leducq Transatlantic Network of Excellence
on atherothrombosis research”), and by T. Bovill (Burlington) and F. Rosendal (Leiden) (« LINAT :
Leducq International Network Against Thrombosis ») : 2004-2007.
Memberships: ERA-EDTA (2010), EURECA-m (2010; elected board member since 2013), European
Society of Hypertension (2004)/ Société de Néphrologie (2005)/Société française d’Hypertension
Artérielle (2002)/Société Francophone de Dialyse 2013
Reviewing : Journal of Hypertension (editorial board member), Arteriosclerosis Thrombosis and
Vascular Biology, Journal of the American College of Cardiology, Journal of Human Hypertension,
Fundamental and Clinical Pharmacology, Clinical Pharmacology and Therapeutics, Advances in Therapy
(editorial board member)
Organization of scientific meetings: CardioVascular Clinical Trialists (CVCT) Forum and Workshop,
chaired by F. Zannad and B. Pitt www.globalcvctforum.com : I am organizing Cardio-Renal sessions
since 2009 (co-course director with G. Bakris, US)
Peer-reviewed publications
2014
1. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Lindholm B, , Mallamaci F,
Martinez-Castelao A, Massy Z, Rossignol P, Suleymanlar G, Vanholder R, Wiecek A,
Zoccali, London GM on behalf of ERA-EDTA EURECAm WG. Epidemiology, contributors
and clinical trials targeting the unacceptably high mortality rates of chronic kidney failure
(glomerular filtration rate <15 ml/min/1.72m2). The Lancet 2014: in press (review)
2. Pitt B, Rossignol P. Mineralocorticoid receptor antagonists in patients with end stage renal
disease (ESRD) on chronic hemodialysis. J Am Coll Cardiol. 2014 ; 63 (6): 537-8
(editorial).
3. Rossignol P, Dobre D, McMurray JJV., Swedberg K, Krum H, van Veldhuisen Dirk J, Shi
H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, and Zannad F
Incidence, determinants, and prognostic significance of hyperkalemia and worsening
renal function in patients with heart failure receiving the mineralocorticoid receptor
antagonist eplerenone or placebo additional to optimal medical therapy. Results from the
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure
(EMPHASIS-HF). Circ Heart Fail. 2014 ;7:51-8.
4. Eschalier R, Rossignol P, Kearney-Schwartz A, Adamopoulos C, Karatzidou K, Fay R,
Mandry D, Marie PY, Zannad F. Features of Cardiac Remodeling, Associated With Blood
Pressure and Fibrosis Biomarkers, Are Frequent in Subjects With Abdominal Obesity.
Hypertension. 2014 Jan 20. [Epub ahead of print]
5. Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, Zannad F.
Incident Hyperkalemia may be An Independent Therapeutic Target In Low Ejection
Fraction Heart Failure Patients. Insights From The HEAAL Study. Int J Cardiol 2014 In
press
6. Regnault V, Lagrange J, Pizard A, Safar M, Fay R, Pitt B, Challande P,
Rossignol P, Zannad F, Lacolley P. Opposite predictive value of pulse pressure and aortic
pulse wave velocity on heart failure with reduced ventricular ejection fraction. Insights
from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy
and Survival Study) substudy. Hypertension. 2014 ;63:105-11.
7. Boivin J.M., Boutte E, Fay R, Rossignol P, Zannad F Home Blood Pressure Monitoring: A
Few minutes of Rest Before Measurement May Not Be Appropriate. American Journal of
Hypertension 2014; doi: 10.1093/ajh/hpu00
8. Cheng JM, Akkerhuis M, Meilhac O, Oemrawsingh RM, Garcia-Garcia HM, van Geuns
RJ, Piquer D, Merle D, du Paty E, Galéa P, Jaisser F, Rossignol P, Serruys PW, Boersma
E, Fareh J, Kardys I. Circulating Osteoglycin and NGAL/MMP9 Complex Concentrations
Predict 1-Year Major Adverse Cardiovascular Events After Coronary Angiography.
Arterioscler Thromb Vasc Biol. 2014 Mar 20. [Epub ahead of print]
9. Mentz R.J, Kjeldsen K, Rossi G.P, Voors A.A, Cleland J.G.F, Anker S.D, Gheorghiade M,
Fiuzat M, Rossignol P, Zannad F, Pitt B; Christopher O’Connor C, Felker G.M.
Decongestion in Acute Heart Failure Eur J Heart Fail. 2014, In press (review)
2013
10. Eschalier R, Fertin M, Fay R, Bauters C, Zannad F, Pinet, Rossignol P. Extracellular
matrix turnover biomarkers predict long term left ventricular remodeling after myocardial
infarction (insights from the REVE-2 study). Circ Heart Fail. 2013;6:1199-205.
11. Martínez-Martínez E, Miana M, Jurado-López R, Rousseau E, Rossignol P, Zannad F,
Cachofeiro V, López-Andrés N, A role for soluble ST-2 in vascular remodeling associated
with obesity in rats. Plos One 2013, PLoS One. 2013; 8:e79176.
12. Eschalier R, McMurray J.J.V , Swedberg K, van Veldhuisen D.J., Krum H, Pocock S.J.,
Shi H, Vincent J, Rossignol P, Zannad F, Pitt B. Safety and efficacy of eplerenone in
patients at high-risk for hyperkalemia and/or worsening renal function: Analyses of
EMPHASIS-HF study subgroups. J Am Coll Cardiol. 2013; 62:1585-93.
13. Vardeny O, Cavallari LH, Claggett B, Desai AS, Anand I, Rossignol P, Zannad F, Pitt B,
Solomon SD. Race Influences the Safety and Efficacy of Spironolactone in Severe Heart
Failure. Circ Heart Fail. 2013 Aug 12. [Epub ahead of print]
14. Delbosc S, Diallo D, Dejouvencel T, Lamiral Z, Louedec L, Martin-Ventura JL, Rossignol
P, Leseche G, Michel JB, Meilhac O. Impaired high-density lipoprotein anti-oxidant
capacity in human abdominal aortic aneurysm. Cardiovasc Res. 2013 Sep 7. [Epub
ahead of print]
15. Rossignol P, Dorval M, Fay R, Fort Ros J, Loughraieb N, Moureau F, Laville M. Rationale
and design of the HepZero study: a prospective multicenter, international, open,
randomized, controlled clinical study with parallel groups comparing heparin-free dialysis
with heparin-coated dialysis membrane (Evodial(R)) versus standard of care. Study
protocol for a randomized controlled trial. Trials Jun 1;14:163.
16. Damman K, Masson S, Hillege H.L., MD, Voors A, van Veldhuisen D.J., Rossignol P,
Proietti G, Barbuzzi S, Nicolosi G.L., Tavazz L, Maggioni A.P., Latini R. Tubular Damage
and Worsening Renal Function in Chronic Heart Failure. JACC: Heart Failure. 10/2013;
1(5):417–424
17. Dobre D, Zannad F, Keteyian S. J., Stevens S, Rossignol P, Kitzman D, Joel Landzberg
J, Howlett, J, Kraus, W.E, Ellis S. Association between Resting Heart Rate, Chronotropic
index and Long-term Outcomes in Patients with Heart Failure Receiving Beta-blocker
Therapy Data from the HF-ACTION Trial Eur Heart J 2013;34:2271-80.
18. López-Andrés N, Calvier L, Labat C, Fay R, Díez J, Benetos A, Zannad F, Lacolley P,
Rossignol P. Absence of cardiotrophin-1 is associated with age-dependant arterial
stiffness and increased longevity in mice. Hypertension 2013; 61:120-9
19. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez- Martinez E, de Boer R, Poirier F,
Lacolley P, Zannad F, Rossignol P, López-Andrés N. Galectin-3 mediates aldosteroneinduced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013; 33:67-75
20. Rossignol P, Hosseini K, Tropeano AI, Fay R, Tsatsaris A, Guillemin F, Mounier-Vehier
C. Target organ damage assessment in French hypertensive patients without established
cardiovascular or renal disease: results of the PREVENT-A study. J Hypertens 2013 ;
31:177-85
21. Rossignol P, Kessler M, Zannad F. Visit-to-visit blood pressure variability and risk for
progression of cardiovascular and renal disease Cur Opinion Nephrol Hypertens 2013;
22:59-64 (review).
22. Rossignol P, F. Zannad. Loop diuretics and ultrafiltration in heart failure. Expert Opinion
Pharmacol 2013 (review);14:1641-8 .
2012
23. Rossignol P, Cleland J, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt
B, Zannad F. Determinants and consequences of renal function variations with
aldosterone blocker therapy in Heart Failure Patients Post Myocardial Infarction. Insights
from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival
Study (EPHESUS). Circulation. 2012;125:271-9.
24. Rossignol P, Cridlig J, Lehert P, Kessler M, Zannad F. Visit-to-visit blood pressure
variability is a strong predictor of cardiovascular events in hemodialysis: insights from
FOSIDIAL. Hypertension. 2012 60:339-46.
25. López-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, Zhao X, Cruickshank
K, Díez J, Zannad F, Lacolley P, Rossignol P. Cardiotrophin-1 is involved in
cardiovascular and renal fibrosis and dysfunction. Hypertension. 2012;60:563-73.
26. Vardeny O, Wu D.H, Desai A, Rossignol P, Zannad F, Pitt B, MD, Solomon SD, for the
Randomized Aldactone Evaluation Study (RALES) Investigators. Influence of Baseline
and Worsening Renal Function on Efficacy of Spironolactone in Patients with Severe HF:
Insights from the RALES Trial. J Am. Coll. Cardiol. 2012; 60:2082-9
27. Dobre D, Rossignol P, Murin J, Parkhomenko A, Lamiral Z, Krum H, van Veldhuisen DJ,
Pitt B, Zannad F. Statin therapy and clinical outcomes in myocardial infarction patients
complicated by acute heart failure: insights from the EPHESUS trial. Eur J Heart Fail.
2012 ; 15:221-7
28. Neisius U, Bilo G, Taurino C, McClure JD, Schneider MP, Kawecka-Jaszcz K, StolarzSkrzypek K, Klima Ł, Staessen JA, Kuznetsova T, Redon J, Martinez F, Agabiti Rosei E,
Melander O, Zannad F, Rossignol P, Laurent S, Collin C, Lonati L, Zanchetti A,
Dominiczak AF, Delles C. Association of central and peripheral pulse pressure with
intermediate cardiovascular phenotypes. J Hypertens. 2012;30:67-74
29. Mandry D, Eschalier R, Kearney-Schwartz A, Rossignol P, Joly L, Djaballah W, Böhme P,
Escanyé JM, Vuissoz PA, Fay R, Zannad F, Marie PY. Comprehensive MRI analysis of
early cardiac and vascular remodeling in middle-aged patients with abdominal obesity. J
Hypertens. 2012;30:567-73.
30. Latouche C, El Moghrabi S, Messaoudi S, Nguyen Dinh Cat A, Hernandez-Diaz I,
Alvarez de la Rosa D, Perret C, López Andrés N, Rossignol P, Zannad F, Farman N,
Jaisser F. Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in
the cardiovascular system. Hypertension. 2012;59:966-72.
31. Ukena C, Dobre D, Mahfoud F, Kindermann I, Lamiral Z, Tala S, Rossignol P, Turgonyi E,
Pitt B, Böhm M, Zannad F. Hypo- and Hyperglycemia Predict Outcome in Patients With
Left Ventricular Dysfunction After Acute Myocardial Infarction: Data From EPHESUS. J
Card Fail. 2012;18:439-45.
32. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JGF, Zannad F,
Lacolley P. Association of Galectin-3 and fibrosis markers with long-term cardiovascular
outcomes in patients with heart failure, left ventricular dysfunction and dyssynchrony.
Insights from the CARE-HF (CArdiac REsynchronization in Heart Failure) Trial. Eur J
Heart Fail. 2012 ;14:74-81.
33. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K,
Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz
RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL,
Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart
failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart
J. 2012; 33:2782-95 (Review)
34. Gustafsson F, Azizi M, Bauersachs J, Jaisser F, Rossignol P. Targeting the aldosterone
pathway in cardiovascular disease. Fundam Clin Pharmacol. 2012;26:135-45. (Review)
35. Dobre D, Rossignol P, Metra M, Zannad F. Can we prevent or treat renal dysfunction in
chronic heart failure ? Heart Fail Rev. 2012;17:283-90. (Review)
2011
36. Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone Survival
benefits in heart failure patients post myocardial infarction are independent from its
diuretic and potassium-sparing effects. Insights from an Eplerenone Post–Acute
Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy. J
Am. Coll. Cardiol. 2011;58:1958–66
37. López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA ,
Cachofeiro V, Díez J. A role for cardiotrophin-1 in myocardial remodeling induced by
aldosterone. Am J Physiol Heart Circ Physiol 2011; 301:H2372-82
38. Boivin JM, Tsou-Gaillet TJ, Fay R, Dobre D, Rossignol P, Zannad F. Influence of the
recommendations on the implementation of home blood pressure measurement by
French general practitioners. A 2004-2009 longitudinal survey J Hypertens 2011:210515.
39. S. Delbosc, J-M. Alsac, C. Journe, L. Louedec, Y. Castier, M. Bonnaure-Mallet, R. Ruimy,
P. Rossignol, P. Bouchard, J-B. Michel, O. Meilhac. Porphyromonas gingivalis
participates in pathogenesis of human Abdominal Aortic Aneurysm by neutrophil
activation. Proof of concept in rats. PLoS ONE 2011,6(4), pp e18679
2010
40. N. Lopez-Andres, M.A. Fortuno, J. Diez, F. Zannad, P. Lacolley, P. Rossignol. Vascular
effects of cardiotrophin-1: a role in hypertension ? J Hypertens 2010, 28(6):1261-72
41. De Jouvencel T, Féron D, Rossignol P, Sapoval M, Kauffmann C, Jean-Marie Piot J-M ,
Michel J-B, Fruitier-Arnaudin I, Meilhac O. Hemorphin 7 reflects hemoglobin proteolysis
.
in abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2010;30:269-75
42. Watfa G, Rossignol P, Kearney-Schwartz A, Fay R, Bracard S, Felblinger J, Boivin JM,
Lacolley P, Zannad F, Benetos A. Use of calcium channel blockers is associated with
better cognitive performance in older hypertensive patients with subjective memory
complaints. Journal Hypertens 2010; 28:2485-93
43. Watfa G, Marteau JB, Rossignol P, Kearney-Schwartz A, Fay R, Bracard S, Felblinger J,
Boivin JM, Lacolley P, Visvikis-Siest S, Benetos A, Zannad F. Association study of gene
polymorphisms involved in vascular alterations in elderly hypertensives with subjective
memory complaints. Genetic variants in cognitive decline and leukoaraiosis. Dementia
and Geriatric Cognitive Disorders 2010;30:440-8
44. Manolopoulou J, Gerum S, Mulatero P, Rossignol P, Plouin PF, Reincke M, Bidlingmaier
M. Salivary Aldosterone as a Diagnostic Aid in Primary Aldosteronism. Horm Metab Res.
2010, 42: 400 – 405
45. Alkerwi A, Guillaume M, Zannad F, Laufs U, Lair ML; NESCAV project group.
Nutrition, environment and cardiovascular health (NESCAV): protocol of an inter-regional
cross-sectional study.BMC Public Health. 2010;10:698.
2009
46. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad
F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction
complicated by left ventricular dysfunction and heart failure: Insights from the EPHESUS
study. Circulation 2009 ;119 :2471-9
47. Pellerin O, Garçon P, Beyssen B, Raynaud A, Rossignol P, Jacquot C, Plouin PF,
Sapoval M. Spontaneous renal artery dissection: long-term outcomes after endovascular
stent placement. J Vasc Interv Radiol. 2009;20:1024-30
48. Joly L, Perret-Guillaume C, Kearney-Schwartz A, Salvi P, Mandry D, Marie PY, Karcher
G, Rossignol P, Zannad F, Benetos A. Pulse wave velocity assessment by external noninvasive devices and phase-contrast magnetic resonance imaging in the obese.
Hypertension 2009;54:421-6
49. Manolopoulou J, Mulatero P, Maser-Gluth C, Rossignol P, Spyroglou A, Vakrilova Y,
Petersenn S, Zvermann O, Plouin P-F, Reinke M, Bildlingmaier M. Saliva as a medium for
aldosterone measurement in repeated sampling studies. Steroids. 2009;74:853-8.
50. Ortiz-Muñoz G, Houard X, Martín-Ventura JL, Ishida BY, Loyau S, Rossignol P, Moreno
JA, Kane JP, Chalkley RJ, Burlingame AL, Michel JB, Meilhac O. HDL anti-elastase
activity prevents smooth muscle cell anoikis, a potential new anti-atherogenic property.
.
FASEB J. 2009;23:3129-39
51. Zannad F, Rossignol P, Iraqi W. Extracellular matrix fibrotic markers in heart failure. Heart
Fail Rev. April 29 [Epub ahead of print]
52. Rossignol P*, Kearney-Schwartz A, Bracard S, Felblinger J, Fay R, Boivin JM, Benetos A,
Zannad F. Vascular structure and function is correlated to cognitive performance and
white matter hyperintensities in older hypertensive patients with subjective memory
complaints. Stroke. 2009;40:1229-1236. *co-first author
53. Houard X, Touat Z, Ollivier V, Louedec L, Philippe M, Sebbag U, Meilhac O, Rossignol P,
Michel JB. Mediators of neutrophil recruitment in human abdominal aortic aneurysms.
Cardiovasc Res. 2009; 82:532-41
2008
54. Boivin J-M, Poupon-Lemarquis L, Iraqi W, fay R, Schmitt C, Rossignol P. A multifactorial
strategy of pain management is associated with less pain in children scheduled
vaccination. A study realized by family practitioners in 239 children aged 4- to 12- yearsold. Fam Pract 2008; 25:423-9
55. Rossignol P, Cambillau M, Bissery A, Mouradian D, Benetos A, Michel J-B, Plouin P-F,
Chatellier G, Jacob M-P. Influence of blood sampling procedure on plasma concentrations
of matrix metalloproteinases and their tissue inhibitors. Clin Exp Pharmacol Physiol.
2008;35:464-9.
56. Plouin PF, Rossignol P, Amar L. Selection of patients for surgery for primary
aldosteronism. Clin Exp Pharmacol Physiol. 2008;35:522-5.
57. Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J,Van Veldhuisen
DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F. Extracellular
matrix turnover and inflammatory markers independently predict functional status and
outcome in chronic heart failure.Collagen markers predict functional capacity. J Card Fail
2008;14:467-74.
2007
58. Rossignol P, Cambillau M, Mouradian D, Plouin PF, Chatellier G, Jacob MP. Variations
with time of plasma concentrations of matrix metalloproteinases 2 and 9 and tissue
inhibitors of matrix metalloproteinases 1 and 2. Thromb Res. 2007; 119 : 261-3
59. Martin-Ventura JL, Leclercq A, Blanco-Colio LM, Egido J, Rossignol P, Michel JB, Meilhac
O. Low plasma levels of HSP 70 in patients with carotid atherosclerosis are associated
with increased levels of proteolytic markers of neutrophil activation. Atherosclerosis
2007;194:334-341.
60. Steichen O, Rossignol P, Daniel-Lebozec C, Charlet J, Jaulent MC, Degoulet P.
Maintenance of a computerized medical record form. AMIA Annu Symp Proc.
2007;11:691-5.
2006
61. Rossignol P, Luttun A, Martin-Ventura JL, Lupu F, Carmeliet P, Collen D, Anglès-Cano E,
Lijnen H-R. Plasminogen activation : a mediator of vascular smooth muscle cell apoptosis
in atherosclerotic plaques. J. Thromb Haemost 2006; 4 : 664-670.
62. Rossignol P, Anglès-Cano E, Lijnen HR. Plasminogen activator inhibitor-1 impairs
plasminogen activation-mediated vascular smooth muscle cell apoptosis. Thromb
Haemost. 2006; 96 : 665-70
63. Caligiuri G, Rossignol P, Julia P, Groyer E, Mouradian D, Urbain D, Misra N, Ollivier V,
Sapoval M, Boutouyrie P, Kaveri S.V, Nicoletti A, Lafont A. Reduced immunoregulatory
CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm. Arterioscler
Thromb Vasc Biol 2006; 26: 618-23.
64. Duet M, Laissy JP, Paulmier B, Rossignol P, Bernard F, Ghazzar-Pierquet N, Faraggi M.
Inflammatory F-18 fluorodeoxyglucose uptake over arterial bypass prosthesis seen on
positron emission tomography can predict acute vascular events. J Nucl Cardiol 2006;
13:876-9
65. Touat Z, Ollivier V, Day J, Huisse MG, Bezeaud A, Sebbag U, Palombi T, Rossignol P,
Meilhac O, Guillin MC, Michel JB. Renewal of mural thrombus releases plasma markers
and is involved in aortic abdominal aneurysm evolution. Am J Pathol. 2006; 168:1022-30
66. Ho-Tin Noe B, Meilhac O, Rossignol P, Lijnen HR, Angles-Cano E. Dual effect of
apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell
detachment of adherent cells. Thromb Haemost. 2006; 95 : 142-50
67. Chedid A, Le Coz S, Rossignol P, Bobrie G, Herpin D, Plouin P-F. Blunt renal traumainduced hypertension : prevalence, presentation and outcome. Am J Hypertens; 2006,
19:500-504.
68. Rossignol P, Chedid A, Bura-Rivière A, Plouin PF. High blood pressure and the risk of
stroke. Curr Med Chem -immunology, endocrine & metabolic agents. 2006; 6 : 385-394
69. Paris B, Bobrie G, Rossignol P, Le Coz S, Chedid A, Plouin P-F. Blood pressure and
renal outcome following renal infarction complicated by hypertension. J Hypertens 2006;
24 : 1649-54
70. Amar L, Peyrard S, Rossignol P, Zinzindohoue F, Gimenez-Roqueplo AP, Plouin PF. The
course of urinary metanephrine excretion in recurrent and malignant pheochromocytomas
and secreting paragangliomas. Ann NY Acad Sci 2006; 1073 : 383-391
2005
71. Long A, Rouet L, Bissery A, Rossignol P, Mouradian D, Sapoval M. Compliance of
abdominal aortic aneurysms evaluated by tissue Doppler imaging: correlation with
aneurysm size. J Vasc Surg. 2005; 42:18-26
2004
72. Long A, Rouet L, Bissery A, Rossignol P, Mouradian D, Sapoval M. Compliance of
abdominal aortic aneurysms: evaluation of tissue imaging. Ultrasound Med Biol. 2004;
9:10099-1108
73. Rossignol P, Bouton MC, Bryckaert M, Jacob M-P, Bezeaud A, Jandrot-Perrus M, Guillin
MC, Michel JB, Meilhac O. A paradoxical pro-apoptotic effect of thrombin on vascular
smooth muscle cells. Exp Cell Res. 2004 ;299:279-85.
74. Rossignol P, Ho-Tin-Noé B, Vranckx R, Bouton MC, Meilhac O, Lijnen H.R, Guillin MC,
Michel JB, Anglès-Cano E. Protease-nexin-1 inhibits plasminogen activation-induced
apoptosis of adherent cells J. Biol Chem 2004 ;279:10346-56
75. Elmadbouh I, Rossignol P, Meilhac O, Vranckx R, Pichon C, Pouzet B, Midoux P, Michel
J-B. Optimization of in vitro vascular cell transfection with non-viral vectors for in vivo
applications J Gene Med. 2004 ;6:1112-24.
2003
76. Bourgeois S, Rossignol P, Grelac F, Chalumeau C, Klein C, Laghmani K, Chambrey R,
Bruneval P, Duong JP, Poggioli J, Houillier P, Paillard M, Kellermann O, Froissart M.
Differentiated thick ascending limb (TAL) cultured cells derived from SV40 transgenic
mice express functional apical NHE2 isoform: effect of nitric oxide. Pflugers Arch.
2003;446:672-83
77. Bouton MC, Richard B, Rossignol P, Philippe M, Guillin MC, Michel JB, Jandrot-Perrus M.
The serpin protease-nexin 1 is present in rat aortic smooth muscle cells and is upregulated in L-NAME hypertensive rats. Arterioscler Thromb Vasc Biol 2003;23:142-7
2002
78. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, Pagano M, Anglès-Cano E,
Michel JB. Involvement of the mural thrombus as a site of protease release and activation
in human aortic aneurysms. Am J Pathol 2002; 161:1701-10.
79. Rossignol P, Chatellier G, Azizi M, Plouin PF : Proteinuria in renal artery occlusion is
related to active renin concentration and contralateral kidney size. J Hypertens 2002; 20 :
139-44
2001
80. Plouin PF, Rossignol P, Bobrie G. Atherosclerotic renal artery stenosis: to treat
conservatively, to dilate, to stent or to operate? J Am Soc Nephrol 2001;12: 2190-2196
81. PF Plouin, P Rossignol, L Stuit, B Guéry. Medication and revascularization for
renovascular disease. Kidney Blood Press Res 2001;24 : 375-377
2000
82. Lidove O, Joly D, Rossignol P, Robino C, N’Guessau K, Grunfeld JP : A man with
proteinuria, familial history of kidney disease, painful extremities and cutaneous lesions.
Nephrol. Dial. Transplant. 2000 ; 15(3):433-435
1999
83. Duvic C, Herody M, Rossignol P, Lecoules S, Didelot F, Nedelec G : Les manifestations
rénales de la sarcoïdose. A propos de neuf observations. Rev. Med. Interne.
1999;20(3):226-33
1995
84. P. Rossignol, F. Bruneel, J.L. Pallot, P. Chauveau, J. Laederich, D. Kleinknecht :
Endocardite pulmonaire compliquée de glomérulonéphrite extracapillaire. Presse Med.
1995;24(17): : 827.
1994
85. F. Freymuth, P. Rossignol, B. Hurault de Ligny, E. Gallet : Méningoencéphalite,
expression d’une primoinfection à virus Epstein - Barr chez un transplanté rénal. Intérêt
de la recherche du génome viral par PCR. Presse Med. 1994; 23(28):1314.
Teaching publications, book chapters
1. Zannad F, Maugendre P, Audry A, and the participants in the round table No. 5 of GIENS XXIX : Avril C,
Blaise L, Blin O, Burnel P, Falise-Mirat B, Girault D, Giri I, Goehrs JM, Lassale C, Le Meur R, Leurent P,
Ratignier-Carbonneil C, Rossignol P, Satonnet E, Simon P, Treluyer L Telemedicine: What framework,
what levels of proof, implementation rules Therapie 2014 In press
2. Alla F, Rossignol P. Méthodologie de la recherche clinique. Rev Prat. 2008 ;58:1483-8.
3. Diebolt V, Pletan Y; Round Table No. 4, Giens XXIII How to improve clinical research performances in
France? Therapie. 2008;63:291-300
4. Rossignol P, Zannad F. Hypertension artérielle résistante. Cardiopros, 2008 ;360 : 5-6.
5. Rossignol P, Plouin P-F.: Traitement médical ou chirurgical de l’Hyperaldostéronisme primaire ? Réalités
cardiologiques 2007, 236 : 25-26.
6. Rossignol P, Amar L, Plouin PF. Hypertensions secondaires à des causes curables chez l’adulte : chez qui
les dépister ? Comment les dépister ? Comment les traiter ? Médecine Thérapeutique, 2007, 13 : 421-8
7. Rossignol P. Anévrysmes et dissection artérielles. In Médecine cardiovasculaire du sujet âgé. MédecineSciences Flammarion 2007
8. Plouin PF, Rossignol P. L’HTA du sujet âgé et/ou athéroscléreux. In des symptômes à la décision. 2007
9. Plouin PF, Rossignol P. La deuxième consultation de l’hypertendu. In des symptômes à la décision. 2006
10. Plouin PF, Rossignol P, Legedz L. Les sténoses dysplasiques des artères rénales. Traité de Cardiologie,
2007
11. Mouradian D, Chedid A, Rossignol P, Postel-Vinay N, Bobrie G, Plouin PF. Hypertension résistante au
traitement : elle impose une démarche systématique bien standardisée pour n’oublier aucune cause. Rev
Prat 2006;20:1205-10
12. Plouin PF, Rossignol P, Bobrie G. Hypertension artérielle du sujet âgé. Bull Acad Natl Med 2006 ; 190 :
793-805.
13. Amar L, Gimenez-Roqueplo AP, Rossignol P, Plouin PF. Hyperaldostéronisme primaire. Traité
d’endocrinologie, Médecine-Sciences Flammarion 2006
14. Amar L, Gimenez-Roqueplo AP, Rossignol P, Plouin PF. Hyperaldostéronisme primaire. EMC 2006
15. Plouin PF, Rossignol P, Amar L. les hyperminéralocorticismes. Médecine Clinique, Endocrinologie &
Diabète 2006 ; 21:9-13
16. Bura-Rivière A, Rossignol P. Thromboangéite oblitérante ou maladie de Buerger. Encycl Méd Chir.
(Elsevier SAS, Paris) 2005, Fascicule 19-1530
17. Rossignol P, Chedid A, Plouin P-F. Bilan d’Hypertension artérielle chez un patient ayant une artériopathie
oblitérante des membres inférieurs. Rev Prat. 2005 ; 55 : 1177-78
18. Rossignol P, Chedid A, Sapoval M, Plouin P-F. Place actuelle de l’angioplastie des sténoses
athéroscléreuses des artères rénales. Sang Thrombose Vaisseaux. 2005; 17 : 209-16
19. Amar L, Gimenez-Roqueplo A-P, Hernigou A, Rossignol P, Plouin P-F. Les tumeurs à rénine. Encycl Méd
Chir. 2005 Fascicule : 10-015-B40
20. Rossignol P, Le Coz S, Plouin P-F. Apport des essais thérapeutiques récents pour le traitement de
l’hypertension artérielle essentielle. Rev Prat 2004 ; 54 : 626-32
21. Rossignol P, Gimenez-Roqueplo A-P, Plouin P-F. Physiologie du système rénine-angiotensine. Cardinale.
2004 ; 9 : 1-4
22. Rossignol P, Gimenez-Roqueplo A-P, Plouin P-F. Exploration du système rénine-angiotensine en pratique
clinique. Cardinale. 2004 ; 9 : 5-9.
23. Rossignol P, Plouin PF. Diurétiques et prévention cardiovasculaire chez l’hypertendu : les apports
d’ALLHAT. Sang Thrombose Vaisseaux. 2003; 15 : 233-235
24. Rossignol P, Cambillau M, Chatellier G, Jacob MP. Indications cliniques de dosages plasmatiques des
métalloprotéases matricielles. Sang Thrombose Vaisseaux. 2003;15 :365-373
25. Rossignol P, Fiquet-Kempf B, Plouin PF. Pathologie des artères rénales. Encycl Méd Chir. (Elsevier SAS,
Paris), Angéiologie, 19-640, 2003, 8p.
26. Plouin PF, Le Coz S, Chedid A, Rossignol P. Indications et résultats de la revascularisation dans la
ème
maladie rénovasculaire d’origine athéroscléreuse. In 29
Séminaire d’uronéphrologie Pitié Salpêtrière, F
Richard, G Deray eds. Paris Atoll ed., 2003, pp.103-6.
27. Patrick Rossignol, Agnès La Batide Alanore, Stéphane Roueff, Guillaume Bobrie, Pierre-François Plouin.
Prise en charge des sténoses athéroscléreuses des artères rénales. J Mal Vasc 2002 ; 27 : 7-11
28. PF Plouin, A La Batide Alanore, B Fiquet-Kempf, P Rossignol, P Launay-Mignot, G Bobrie. Hypertensions
secondaires à des causes curables chez l’adulte. Press Med 2002 ; 31 : 371-8
29. Patrick Rossignol, Vincent Fontaine, Olivier Meilhac, Eduardo Anglés-Cano, Marie-Paule Jacob et JeanBaptiste Michel. Physiopathologie des anévrysmes de l’aorte. Rev Prat. 2002; 10:1061-5
30. Patrick Rossignol, Vincent Fontaine, Marie-Paule Jacob, Eduardo Anglés-Cano et Jean-Baptiste Michel.
Protéolyse et anti-protéolyse dans la maladie aortique anévrysmale. Sang Thrombose Vaisseaux.
2001;13 : 348-354
31. Rossignol P, Plouin PF : Faut-il encore dilater les sténoses athéroscléreuses de l’artère rénale ? Rev Prat.
2001;51:1165-6.
Invited lectures
1. Patrick Rossignol, Vincent Fontaine, Olivier Meilhac, Eduardo Anglés-Cano, Marie-Paule Jacob et JeanBaptiste Michel. Physiopathologie des anévrysmes : protéolyse et anti-protéolyse dans la maladie aortique
anévrysmale. Société d’Angiologie de langue française.15/03-2002, Paris.
2 Patrick Rossignol. Fibrodysplasie artérielle des membres inférieurs. Société Française de Médecine
Vasculaire, Bordeaux, 2005.
rd
3 Patrick Rossignol. Management of atherosclerotic renal artery stenosis. 23 International Meeting on
Clinical Cardiology, Hellenic Heart Foundation, 1/05/2008, Athènes
4 Patrick Rossignol. Combien d’hypertendus évoluent vers l’insuffisance cardiaque ? Combien d’insuffisants
cardiaques sont ou étaient hypertendus ? Printemps de la Cardiologie, Société française de Cardiologie.
30/05/2008, Montpellier.
5 Patrick Rossignol. Traitement médical des anévrysmes de l’aorte abdominale. Société française de
médecine vasculaire. 2/10/2008, Nice.
6 Patrick Rossignol. Sténose artérielle rénale : quelle attitude en pratique ? Printemps de la cardiologie, 12
juin 2009, Nancy
7 Patrick Rossignol Biomarkers of renal injury in heart failure. International Workshop on heart Failure
biomarkers Cannes avril 2009
8 Patrick Rossignol Biomarkers of kidney injury in heart failure International Workshop on heart Failure
biomarkers Cannes 16-17 octobre 2010
9 Patrick Rossignol Sténoses athéroscléreuses artérielles rénales : qoui de neuf ? Actualités néphrologiques
Hôpital Necker-Enfants Malades, 6/04/2011
10 Patrick Rossignol Place des antialdostérones dans la prise en charge de l’insuffisance cardiaque, l’avis du
néphrologue Actualités cardio-néphrologiques, Nice, 15 juin 2011
11 Patrick Rossignol "Aldosterone antagonism in CKD and in ESRD: effectiveness and safety", Prague, ERAEDTA/EURECAm symposium, 25/06/2011
12 Patrick Rossignol Place des antialdostérones dans la prise en charge de l’insuffisance cardiaque et rénale,
l’avis du néphrologue Actualités cardio-néphrologiques, Paris, 15 septembre 2011
13 Patrick Rossignol Place des antialdostérones dans la prise en charge de l’insuffisance cardiaque et rénale.
Société de Néphrologie, Bordeaux, 5/10/2011
14 Patrick Rossignol The use of mineralocorticoid receptor antagonist (MRA) in clinical practice.
Understanding, predicting, preventing and managing renal and potassium safety issues. Cardiovascular
Trialist Forum; Paris, 3/12/11
15 Patrick Rossignol Biomarkers of renal injury in heart failure. International Workshop on heart Failure
biomarkers Cannes avril 2012
ème
16 Patrick Rossignol Traitement médical de l’insuffisance cardiaque : place des antialdostérones. Pro. 6
réunion « Prise en charge précoce de la maladie rénale chronique « Comprendre et traiter le syndrome
cardio-rénal » Mai 2012, Montpellier.
17 Patrick Rossignol RAAS inhibition (FOSIDIAL, ALCHEMIST) Cardiovascular Trialist Forum; Paris, 1/12/12
18 Patrick Rossignol. Traitement antihypertenseur en hémodialyse ; Séminaires Universitaires de
Néphrologie ; Paris, 24/1/13
19 Patrick Rossignol. Essais HEMO, MPO, FOSIDIAL…Peut-on améliorer le pronostic cardiovasculaire des
hémodialysés ? 2è Assises Rénal Pharma ; Paris, 21/03/13
20 Patrick Rossignol Emerging Biomarkers and Therapeutic Choices in heart failure – Planned Research and
Current Evidence. International Workshop on heart Failure biomarkers Cannes avril 2013
21 Patrick Rossignol. P2T de l’aldostérone et de ses antagonistes : de la paillasse au domicile du patient
(P2T, Session jeune chercheur, nominé par l’APNET, Angers, avril 2013)
22 Patrick Rossignol. Société de Néphrologie, Antagonistes des récepteurs minéralocorticoides. Nantes,
octobre 2013